臭氧联合培菲康治疗溃疡性结肠炎临床疗效及对细胞因子IL-6、TGF-1水平的影响被引量：10

导出

摘要目的:探讨臭氧联合培菲康治疗对溃疡性结肠炎(UC)患者细胞因子IL-6、TGF-1的影响及疗效。方法:将72例溃疡性结肠炎患者随机分为两组,对照组36例给予单独口服培菲康420mg,3次/d;治疗组36例口服培菲康420mg,3次/d;配合臭氧灌肠治疗1次/d,15次为1个疗程;两组均治疗15d,观察两组治疗前后的临床症状、肠镜检查情况,以及患者血清中IL-6和TGF-1水平。结果:治疗组治愈率(94.44%)明显高于对照组(86.11%),经比较差异有统计学意义,治疗组和对照组治疗15d后,IL-6和TGF-1水平明显低于治疗前,两者相比,差异有统计学意义。结论:臭氧联合培菲康治疗溃疡性结肠炎的疗效优于对照组,无不良反应发生,明显降低患者血清IL-6、TGF-1的水平,值得在临床中推广应用。

作者高三明

机构地区陕西省渭南市第二医院内三科

出处《陕西医学杂志》 CAS 2013年第7期895-897,共3页 Shaanxi Medical Journal

关键词臭氧治疗应用白细胞介素6 分析转化生长因子分析 @培菲康结肠炎溃疡性药物疗法

分类号 R574.6 [医药卫生—消化系统]

引文网络
相关文献

参考文献11

1Brandtzaeg P. In flammatory bow el disease., clinics and pathology. Do inf lammat ory bow el disease and periodont al disease have sim-ilar immunopathogeneses [J]. Act a- Odontol- Scand, 2001, 59(4) : 235-243.
2Sands BE, Kaplan GG. T he role of TNFalpha in ulcera tive coiit is[J]. J Ciin Pharmacol, 2007, 47(8) : 930- 941.
3中华医学会消化病学分会炎症性肠病协作组,欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见(2007年，济南)[J].中华消化杂志,2007,27(8):545-550. 被引量：1033
4欧阳钦,潘国宗,温忠慧,万学红,胡仁伟,林三仁,胡品津.对炎症性肠病诊断治疗规范的建议[J].中华消化杂志,2001,21(4):236-239. 被引量：1125
5谭琰,邹开芳,杨天,陈胜,侯晓华,潘庆华.微生态制剂对溃疡性结肠炎患者治疗前后临床疗效观察[J].中华消化内镜杂志,2008,25(2):77-81. 被引量：50
6卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的实验性研究[J].现代预防医学,2005,32(7):735-736. 被引量：54
7Reddy KP, Markowitz JE, Ruchelli ED, et all Lamina p rop ria and circulating interleukin28 in newly and p revi- ously diagnosed pediatric inflammatory bowel disease pa- tients1 Dig Dis Sci, 2007, 52 ( 2 ) :3652-3721.
8Bickerst af A, Orosz C. Evidence f or a limited cont ribut ion of immune regulation to allograf t accept ante[ J] . Hum Immunol, 2002,63(10) : 935.
9Monteleone G, Boirivant M, Pallon e F, etal. TGF- bet al and Smad7 in the regulat ion of IBD[J ] . M ucosal Im- munol, 2008, 1(1) : 50- 53.
10卢健,马骥,王丽娜,等.四逆散对实验性大鼠血TNF-α和IL-IO的影响[J].陕西中医,2010,33(6):61.

二级参考文献34

1徐大毅.溃疡性结肠炎药物治疗的现状[J].中华消化杂志,1994,14(2):65-66. 被引量：74
2Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol,2005,100 : 1539 -1546.
3Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1 ) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut ,2005,54:242-249.
4Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update) : American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol,2004, 99:1371-1385.
5Pullan RD, Rhodes J, Ganesh S,et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med,1994,330:811-815.
6Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis, 2004, 10:286- 299.
7Guarner C, Runyon BA, Young S,et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol, 1997,26 : 1372-1378.
8Fiocchi C. Microbial factors in the pathogenesis of IBD. Bioscience Microflora,2003 ,22 :5-14.
9Marteau P, Lepage P, Mangin I, et al. gut flora and inflammatory bowel disease. Aliment Phannacol Ther,2004,20( Suppl 4) : 18- 23.
10Weaver KD,Grossman SA,Herman JG.Methylated tumor-specific DNA as a plasma biomarker in patients with glionma[J].Cancer Invest,2006,24(1):35-40.